Table 1. Presenting features and early response according to ETV6-RUNX1 status in patients with B-precursor ALL.
| Clinical Features | All patients [N (%)] N=662 | ETV6-RUNX1 positive [N (%)] N=168 | ETV6-RUNX1 negative [N (%)] N=494 | P-value | |
|---|---|---|---|---|---|
| Age Groups | < 1 year | 12 (1.8) | 0 (0.0) | 12 (2.4) | <.0001 |
| 1-10 years | 498 (75.2) | 157 (93.5) | 341 (69.0) | ||
| > 10 years | 152 (23.0) | 11 (6.5) | 141 (28.5) | ||
| Initial WBC | <50 ×109/L | 527 (79.6) | 137 (81.5) | 390 (79.0) | 0.51 |
| ≥50 ×109/L | 135 (20.4) | 31 (18.5) | 104 (21.0) | ||
| Race | White | 529 (79.9) | 128 (76.2) | 401 (81.2) | 0.22 |
| Black | 97 (14.7) | 27 (16.1) | 70 (14.2) | ||
| Other | 36 (5.4) | 13 (7.7) | 23 (4.7) | ||
| Gender | Male | 361 (54.5) | 88 (52.4) | 273 (54.9) | 0.53 |
| Female | 301 (45.5) | 80 (47.6) | 221 (45.1) | ||
| NCI/Rome Risk group | Standard risk | 401 (60.6) | 127 (75.6) | 274 (55.5) | <.0001 |
| High risk | 261 (39.4) | 41 (24.4) | 220 (44.5) | ||
| SJ Risk Group | Low risk | 318 (48.0) | 111 (66.1) | 207 (41.9) | <.0001 |
| Standard/High risk | 344 (52.0) | 57 (33.9) | 287 (58.1) | ||
| CNS status | CNS1 | 472 (71.3) | 141 (83.9) | 331 (67.0) | 0.0002 |
| CNS2 | 141 (21.3) | 20 (11.9) | 121 (24.5) | ||
| CNS3 | 9 (1.4) | 0 (0.0) | 9 (1.8) | ||
| Traumatic with blasts | 40 (6.0) | 7 (4.2) | 33 (6.7) | ||
| MRD day 19 | <0.01% | 199 (42.9) | 63 (59.4) | 136 (38.0) | <.0001 |
| ≥0.01 to <1% | 179 (38.6) | 39 (36.8) | 140 (39.1) | ||
| ≥1% | 86 (18.5) | 4 (3.8) | 82 (22.9) | ||
| MRD day 46 | <0.01% | 376 (80.2) | 97 (88.2) | 279 (77.7) | 0.01 |
| ≥0.01 to <1% | 77 (16.4) | 13 (11.8) | 64 (17.8) | ||
| ≥1% | 16 (3.4) | 0 (0.0) | 16 (4.5) | ||
| Treatment protocol | Total XIIIA | 114 (17.2) | 36 (21.4) | 78 (15.8) | 0.19 |
| Total XIIIB | 144 (21.8) | 38 (22.6) | 106 (21.4) | ||
| Total XV | 404 (61.0) | 94 (55.9) | 310 (62.8) | ||
WBC: white blood cell; NCI: National Cancer Institute; SJ: St Jude; CNS: central nervous system; MRD: Minimal residual disease